Literature DB >> 29120662

Comparison of MRI visualization between linearly placed iron-containing and non-iron-containing fiducial markers for prostate radiotherapy.

Osamu Tanaka1, Hisao Komeda2, Masayoshi Tamaki2, Kensaku Seike2, Shota Fujimoto2, Eiichi Yama3, Shigeki Hirose3, Masayuki Matsuo4.   

Abstract

OBJECTIVE: Visualizing the gold marker (GM) in CT and MRI is critical, especially for registration in high-precision radiotherapy. GM sizes vary. Large markers are easily visualized in MRI. Small GMs show fewer artefacts in CT but are harder to detect in MRI because the signal is influenced by metal in MRI. Therefore, we compared MRI visualization between linearly placed new iron-containing marker and non-iron containing marker.
METHODS: 27 patients underwent CT/MRI fusion-based intensity-modulated radiotherapy. The gold markers were placed by urologists. An iron-containing Gold Anchor™ (GA) marker (diameter, 0.28 mm; length, 10 mm) was placed by using a 22 G needle on one side of the prostate linearly. A non-iron-containing VISICOIL™ (VIS) marker (diameter, 0.35 mm; length, 10 mm) was placed by using a 19 G needle on the opposite side linearly. T2* weighted MRI was mostly performed. Two Radiation Oncologists and one Radiation Technologist evaluated and assigned visual quality scores (GA shape, CT artefacts, MRI signal voids).
RESULTS: The mean visualization scores of artefacts were similar between GA and VIS in planning CT. GM visualization in MRI of the prostate was better for GA than for VIS. The visibility of the linear shape of the GA was 3.4-4.1 points when the VIS was 5 points (1 is worst and 5 is best).
CONCLUSION: Visualization quality was similar between GA (iron-containing marker) and VIS (non-iron-containing marker) in planning CT, but was better for GA than for VIS in MRI. To achieve high-precision radiotherapy, an iron-containing gold marker was useful for CT and MRI registration. Advances in knowledge: An iron-containing fiducial marker was useful for CT and MRI registration, especially in high-precision radiotherapy, such as stereotactic body radiotherapy and intensity-modulated radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29120662      PMCID: PMC5965782          DOI: 10.1259/bjr.20170612

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  12 in total

1.  Impact of prostate volume evaluation by different observers on CT-based post-implant dosimetry.

Authors:  Bashar Al-Qaisieh; Dan Ash; David M Bottomley; Brendan M Carey
Journal:  Radiother Oncol       Date:  2002-03       Impact factor: 6.280

2.  Interobserver variation in postimplant computed tomography contouring affects quality assessment of prostate brachytherapy.

Authors:  Juanita Crook; Michael Milosevic; Pamela Catton; Ivan Yeung; Tara Haycocks; Thao Tran; Charles Catton; Michael McLean; Tony Panzarella; Masoom A Haider
Journal:  Brachytherapy       Date:  2002       Impact factor: 2.362

3.  Characterizing interfraction variations and their dosimetric effects in prostate cancer radiotherapy.

Authors:  Cheng Peng; Ergun Ahunbay; Guangpei Chen; Savannah Anderson; Colleen Lawton; X Allen Li
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-21       Impact factor: 7.038

4.  Comparison of MRI-based and CT/MRI fusion-based postimplant dosimetric analysis of prostate brachytherapy.

Authors:  Osamu Tanaka; Shinya Hayashi; Masayuki Matsuo; Kota Sakurai; Masahiro Nakano; Sunaho Maeda; Kimihiro Kajita; Takashi Deguchi; Hiroaki Hoshi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-10-01       Impact factor: 7.038

5.  Interobserver variability leads to significant differences in quantifiers of prostate implant adequacy.

Authors:  W Robert Lee; Mack Roach; Jeff Michalski; Brian Moran; David Beyer
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-10-01       Impact factor: 7.038

6.  Intraobserver and interobserver variability of MR imaging- and CT-derived prostate volumes after transperineal interstitial permanent prostate brachytherapy.

Authors:  D F Dubois; B R Prestidge; L A Hotchkiss; J J Prete; W S Bice
Journal:  Radiology       Date:  1998-06       Impact factor: 11.105

7.  Fiducial marker for prostate radiotherapy: comparison of 0.35- and 0.5-mm-diameter computed tomography and magnetic resonance images.

Authors:  Osamu Tanaka; Hisao Komeda; Takayoshi Iida; Masayoshi Tamaki; Kensaku Seike; Daiki Kato; Shigeki Hirose; Daisuke Kawaguchi; Takamasa Yokoyama
Journal:  Radiol Med       Date:  2016-12-15       Impact factor: 3.469

8.  Visibility and artifacts of gold fiducial markers used for image guided radiation therapy of pancreatic cancer on MRI.

Authors:  Oliver J Gurney-Champion; Eelco Lens; Astrid van der Horst; Antonetta C Houweling; Remy Klaassen; Jeanin E van Hooft; Jaap Stoker; Geertjan van Tienhoven; Aart J Nederveen; Arjan Bel
Journal:  Med Phys       Date:  2015-05       Impact factor: 4.071

9.  Qualitative evaluation of fiducial markers for radiotherapy imaging.

Authors:  Maria F Chan; Gil'ad N Cohen; Joseph O Deasy
Journal:  Technol Cancer Res Treat       Date:  2014-09-16

10.  Strategies for online organ motion correction for intensity-modulated radiotherapy of prostate cancer: prostate, rectum, and bladder dose effects.

Authors:  Erik-Jan Rijkhorst; Annemarie Lakeman; Jasper Nijkamp; Josien de Bois; Marcel van Herk; Joos V Lebesque; Jan-Jakob Sonke
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-11-15       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.